Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

A customized and versatile high-density genotyping array for the mouse.

Yang H, Ding Y, Hutchins LN, Szatkiewicz J, Bell TA, Paigen BJ, Graber JH, de Villena FP, Churchill GA.

Nat Methods. 2009 Sep;6(9):663-6. doi: 10.1038/nmeth.1359. Epub 2009 Aug 9.

2.

Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans.

Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, Harris SC, Smith PC, Tennant R, Bogue M, Paigen K, Harris C, Contractor T, Wiltshire T, Rusyn I, Threadgill DW.

Genome Res. 2009 Sep;19(9):1507-15. doi: 10.1101/gr.090241.108. Epub 2009 May 5.

3.

Identification of quantitative trait loci for locomotor activation and anxiety using closely related inbred strains.

Bailey JS, Grabowski-Boase L, Steffy BM, Wiltshire T, Churchill GA, Tarantino LM.

Genes Brain Behav. 2008 Oct;7(7):761-9.

4.

High-resolution genetic mapping of mammalian motor activity levels in mice.

Kas MJ, de Mooij-van Malsen JG, de Krom M, van Gassen KL, van Lith HA, Olivier B, Oppelaar H, Hendriks J, de Wit M, Groot Koerkamp MJ, Holstege FC, van Oost BA, de Graan PN.

Genes Brain Behav. 2009 Feb;8(1):13-22. doi: 10.1111/j.1601-183X.2008.00435.x. Epub 2008 Aug 21.

5.

Antipsychotic-induced extrapyramidal symptoms and their management.

Dayalu P, Chou KL.

Expert Opin Pharmacother. 2008 Jun;9(9):1451-62. doi: 10.1517/14656566.9.9.1451 . Review.

PMID:
18518777
6.

Criteria for validating mouse models of psychiatric diseases.

Chadman KK, Yang M, Crawley JN.

Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):1-11. doi: 10.1002/ajmg.b.30777. Review.

7.

Tardive dyskinesia.

Soares-Weiser K, Fernandez HH.

Semin Neurol. 2007 Apr;27(2):159-69. Review.

PMID:
17390261
8.

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.

Bakker PR, van Harten PN, van Os J.

Schizophr Res. 2006 Apr;83(2-3):185-92. Epub 2006 Mar 2.

PMID:
16513329
9.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

10.

Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):33-43. Epub 2005 Sep 19.

PMID:
16171976
11.
12.

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP.

Pharmacogenet Genomics. 2005 Mar;15(3):151-8.

PMID:
15861039
13.
14.

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy.

Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN.

J Pharmacol Exp Ther. 2003 May;305(2):625-31. Epub 2003 Feb 20. Erratum in: J Pharmacol Exp Ther. 2006 May;317(2):919.

15.

The effect of ovariectomy and long-term estrogen replacement on bladder structure and function in the rat.

Fleischmann N, Christ G, Sclafani T, Melman A.

J Urol. 2002 Sep;168(3):1265-8.

PMID:
12187279
16.

The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?

Turrone P, Remington G, Nobrega JN.

Neurosci Biobehav Rev. 2002 May;26(3):361-80. Review.

PMID:
12034136
17.

Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation.

Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Koshikawa N, Waddington JL.

Eur J Pharmacol. 2001 Apr 20;418(1-2):47-54.

PMID:
11334864
18.

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.

Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL.

Mol Psychiatry. 2001 Mar;6(2):230-4.

19.

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.

Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U, Klein HE, Rohrmeier T.

Am J Med Genet. 2000 Apr 3;96(2):187-91.

PMID:
10893495
20.

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.

Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL.

Neuropsychopharmacology. 1999 Jul;21(1):17-27.

Supplemental Content

Support Center